Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. reported equity compensation grants to Chief Business & Strategy Officer Otitoju Kolawole A. on April 21, 2026. He received 110,193 restricted stock units, each representing one share of common stock, vesting in three substantially equal annual installments on the anniversaries following May 1, 2026, subject to continued service.
He was also granted a stock option for 146,789 shares of common stock at an exercise price of $7.26 per share, expiring on April 20, 2036. One-third of these option shares vest on May 1, 2027, with the remaining two-thirds vesting in substantially equal monthly installments over the following 24 months, contingent on continued service. These are compensation awards rather than open-market purchases or sales.
908 Devices Inc. filed an initial ownership report on Form 3 for Otitoju Kolawole A., who serves as Chief Business & Strategy Officer. This filing establishes his status as an officer and discloses that there are currently no reportable transactions or holdings listed in this statement.
908 Devices Inc. senior vice president Kevin J. McCallion exercised stock options for 2,693 shares of common stock at $1.05 per share and sold the same 2,693 shares at a weighted average price of $7.01 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was pre‑scheduled. Following the transactions, he directly holds 44,925 shares of common stock, and the underlying option grant is now fully exercised.
908 Devices Inc. senior vice president Kevin J. McCallion exercised employee stock options and immediately sold the resulting shares in planned trades. He exercised options for 24,000 shares of common stock at $1.05 per share, then sold 24,000 shares in open-market transactions at weighted-average prices around $7.04 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was scheduled in advance. After these transactions, McCallion directly holds 44,925 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported open-market sales of 40,000 shares of Common Stock. The transactions occurred over three days at prices around $7 per share, under a Rule 10b5-1 trading plan adopted on November 24, 2025.
Brown sold 15,030 shares at a weighted average price of $7.05 on April 8, 7,392 shares at $7.04 on April 9, and 17,578 shares at $7.07 on April 10. After these sales, he continues to hold 945,559 shares directly, indicating he retains a substantial equity position in the company.
Kevin McCallion reported a proposed sale of 27,000 shares of Common Stock via exercise of stock options on 04/08/2026. The filing lists the method as a cash exercise with sales planned through the issuer on NASDAQ. The record also lists prior 10b5-1 sales earlier in 2026 (including 9,438 and 9,000 share transactions).
908 Devices Inc. registers up to $100,000,000 of securities on a shelf for issuance from time to time. The shelf permits offerings of common stock, preferred stock, debt securities, warrants and/or units in one or more series, with specific terms set in prospectus supplements. The company’s common stock trades on the Nasdaq Global Market under the symbol MASS; the closing price reported on March 5, 2026 was $6.75 per share. The prospectus emphasizes investor risk factors and incorporates the company’s Annual Report on Form 10-K for the year ended December 31, 2025 by reference.
908 Devices Inc. files its annual report describing a business focused on handheld chemical analysis devices for critical health, safety and defense applications. The company builds portable mass spectrometry and optical spectroscopy instruments that let front-line users identify unknown drugs, explosives, toxic chemicals and gases at the point of need.
Since launching its first device in 2014, it has sold more than 3,700 handheld units to over 700 customers, including numerous government agencies, and more than 3,100 MX908 devices with over 14,000 trained operators. The report outlines its technology platform, product portfolio, manufacturing footprint, intellectual property, regulatory environment, cybersecurity posture and extensive risk factors tied to macroeconomic conditions, competition, supply chain and data security.